Skip to content
Tuesday 28 July 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
City PM

European business, markets and politics

FTSE 100
10,781.75
+0.42%
DAX
25,361.03
0.00%
CAC 40
8,406.06
0.00%
STOXX 50
6,282.21
0.00%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Sponsored Ad Feature is produced by an advertiser with the specific intent to promote a product and is not produced by the City PM team.
Wednesday 29 December 2021 9:00 am  |  Updated:  Friday 24 December 2021 9:48 am

Try a new drug-free treatment for Alzheimer’s

By:

Add as a preferred source on Google

NeuroPulse Transcranial Pulse Stimulation is a new treatment for Alzheimer’s disease and mild to moderate dementia.

It’s currently the only drug-free treatment clinically proven to enhance and maintain cognitive ability in Alzheimer’s patients. The treatment is comfortable and non-invasive, with just six 30-minute treatments over two weeks, which can improve mild to moderate Alzheimer’s by 10 points on the CERAD scale.

It works through the TPS passing high-frequency acoustic pulses through the patient’s head to stimulate deep cerebral regions of the brain, which stimulates neural growth factors. To perform the procedure, a machine called a Neurolith is used; it was created by Storz Medical, one of Europe’s leading medical machine manufacturers since 1987, and is sold in the UK by Venn Healthcare.

For more information on the treatment and eligibility, visit alzheimersclinics.co.uk

Read more

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Life&Style

Categories

  • Life&Style

Trending Articles

  • Big Four’s AIM exodus accelerates as mid-tier firms seize mandates

  • FTSE 100 firm agrees £5.7bn takeover in latest private equity swoop

  • Burnham backs plan to pump £1bn pension funds into start-ups

  • Scotland’s tax hike may have backfired as receipt falls

  • As it happened: Stocks rise; oil falls after Trump pauses Iran strikes

More from City PM

  • Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

    Business Wire
  • Almirall Announces EMA Acceptance for Filing of Paediatric Registration of Ebglyss (Lebrikizumab) in Atopic Dermatitis in Children 6 Months and Older

    Business Wire
  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
  • ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026

    Business Wire
  • Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform

    Business Wire
  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • Tenpoint Therapeutics Announces United Kingdom Submission of Marketing Authorization Application to the Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

    Business Wire
  • Almirall H1 2026 Results

    Business Wire
CityPM

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About City PM
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 City PM Ltd · Published by CityPM Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook